In this webinar, Dr. Yuting Sun discusses her research supporting a Phase 1 clinical trial advancing cancer therapies, targeted at metabolic vulnerabilities. Metabolic rewiring is a hallmark of cancer. However, the plasticity of preexisting regulatory circuit compromises the effectiveness of targeted therapies. We postulate that leveraging genetic vulnerabilities in cancer cells may overcome such adaptations. In this presentation, we discuss strategies in targeting two distinct metabolic vulnerabilities- FHmut cancer and glycolysis-deficient cancer.
1. Targeting redox balance in FHmut cancer
2. Targeting OXPHOS in glycolysis deficient tumor
3. Utilization of seahorse assay supporting Phase 1 clinical trial (for research use)